Novo Nordisk A/S - Share Repurchase Programme
Date
11/8/2024 4:00:53 PM
(MENAFN- GlobeNewsWire - Nasdaq) Bagsværd, Denmark, 8 November 2024 – The execution of Novo Nordisk A/S' overall share repurchase programme for 2024 of DKK 20 billion continues. As part of this, Novo Nordisk A/S has now initiated a new share repurchase programme of up to DKK 3,136,206,122.30 in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules”). The purpose of the programme is to reduce the company's share capital and to meet obligations arising from share-based incentive programmes. B shares of DKK 0.10 will be repurchased during the trading period starting 11 November 2024 and ending on 3 February 2025. A maximum of 400,000,000 B shares of DKK 0.10 in total can be bought during the trading period.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 72,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook , Instagram , X , LinkedIn and YouTube .
Contacts for further information
| Media: | |
Ambre James-Brown
+45 3079 9289
...
| Liz Skrbkova (US)
+1 609 917 0632
...
|
| Investors: | |
Jacob Martin Wiborg Rode
+45 3075 5956
...
| David Heiberg Landsted
+45 3077 6915
...
|
Sina Meyer
+45 3079 6656 ...
| Ida Schaap Melvold
+45 3077 5649 ...
|
Frederik Taylor Pitter
+1 609 613 0568
...
| |
Company announcement No 85 / 2024
Attachment
CA241108-SafeHarbour-initiation
MENAFN08112024004107003653ID1108866759
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.